Unlabelled somatostatin analogues in treatment of digestive endocrine tumours

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 1, 2004, Pages

  Panzuto, F ^a   Nasoni, S ^a   Baccini, F ^a   Cassetta, S ^a   Corleto, V D ^a   Delle Fave, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Endocrine tumours; Interferon; Lanreotide; Octreotide; Somatostatin analogues

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TUMOR MARKER; DRUG DERIVATIVE; INTERFERON; SOMATOSTATIN;

ABDOMINAL PAIN; ASTHENIA; CARCINOID SYNDROME; COLON CANCER; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE TUMOR; FLATULENCE; GALLSTONE; GASTRINOMA; GLUCAGONOMA; GLUCOSE INTOLERANCE; HUMAN; INJECTION PAIN; NAUSEA; OVARY CANCER; PANCREAS CANCER; PATIENT COMPLIANCE; PROSTATE CANCER; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; SYMPTOM; TREATMENT OUTCOME; TUMOR GROWTH; VIPOMA; ZOLLINGER ELLISON SYNDROME; DIGESTIVE SYSTEM TUMOR; DRUG COMBINATION; NEUROENDOCRINE TUMOR;

DIGESTIVE SYSTEM NEOPLASMS; DRUG THERAPY, COMBINATION; HUMANS; INTERFERONS; NEUROENDOCRINE TUMORS; SOMATOSTATIN;

EID: 2442685658     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.11.013     Document Type: Article

References (42)

1. Reubi JC, Waser B, Schaer JC, Laissaue JA. Somatostatin receptors sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
2. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60.
3. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
4. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998;76:259-66.
5. Garcia de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol 2002;57:425-41.
6. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of long-acting somatostatin analogue. N Engl J Med 1986;315:663-6.
7. Lamberts SWJ, Van der Lely AJ, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
8. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10:S31-8.
9. Corleto VD, Angeletti S, Schillaci O, Marignani M, Caratozzolo M, Panzuto F, et al. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol 2000;11:491-3.
10. Angeletti S, Corleto VD, Schillaci O, Moretti A, Panzuto F, Annibale B, et al. Single dose of octreotide stabilizes metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999;31:23-7.
11. Gorden P, Comi RJ, Maton PN, Go VL. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non neoplastic disease of the gut. Ann Intern Med 1989;110:35-50.
12. Öberg K, Funa K, Aim G. Effects of leukocyte interferon upon clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983;309:129-33.
13. Janson ET, Ahlström H, Andersson T, Öberg K. Octreotide and interferon-α: a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992;28:1647-50.
14. Rubin J, Ajani J, Schrimer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6.
15. Wymenga ANM, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJDG, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111-7.
16. Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999;31:216-8.
17. Caron PH, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104.
18. Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;456:45-9.
19. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insuline- like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143:4123-30.
20. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2- pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1998;95:1794-9.
21. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127-30.
22. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23:412-5.
23. Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, et al. Sandostatin LAR for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-44.
24. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, et al. Treatment of carcinoid syndrome. A prospective cross over evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6.
25. Ducreux M, Ruszniewsky P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-81.
26. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-60.
27. Aparicio T, Ducreux M, Baudin E, Sabourin J-C, De Baere T, Mitry E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-9.
28. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-8.
29. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041-4.
30. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-8.
31. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999;60:469-76.
32. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002;94:331-43.
33. Redfern JS, Fortuner WJ. Octreotide-associated biliary tract dysfunction and gallstones formation: pathophysiology and management. Am J Gastroenterol 1995;90:1042-52.
34. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cells tumors. Cancer 1997;79:830-4.
35. Eriksson B. Medical treatment of gastroenteropancreatic tumors with octreotide plus interferon. In: The expanding role of octreotide. I. Advances in oncology. Lamberts, Dogliotti (Bristol): BioScientifica; 2002. p. 103-12.
36. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
37. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42.
38. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, et al. Targeted cytotoxic somatostatin analogue AN238 inhibits somatostatin receptor positive experimental colon cancers independently of their p53 status. Cancer Res 2002;62:781-8.
39. Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, et al. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN238. Cancer 2001;92:1168-76.
40. Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, et al. Targeting of cytotoxic somatostatin analog AN238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer. Clin Cancer Res 2001;7:2854-61.
41. Benali N, Cordelier P, Cause D, Pagès P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN238. Proc Natl Acad Sci USA 2000;97:9180-5.
42. Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowsky A, Halmos G. Targeted cytotoxic analogue of somatostatin AN238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 1998;58: 4132-7.